Helmholtz Center for Infection Research, Chemical Microbiology, Inhoffenstrasse 7, 38124 Braunschweig, Germany.
Curr Med Chem. 2011;18(18):2791-815. doi: 10.2174/092986711796011274.
The purine ribonucleoside adenosine (Ado) has been recognized for its regulatory functions in situations of cellular stress like ischemia, hypoxia and inflammation. The importance of extracellular Ado as a modulator in the immune system is a theme of great appreciation and the focus of recent increasing interest in the field of gastrointestinal inflammation. In this review, the different aspects of Ado signaling during inflammatory responses in the gut are discussed, considering the contribution of the four known Ado receptors (ARs; A(1), A(2A), A(2B), and A(3)), their mechanisms and expression patterns. Activation of these receptors in epithelial cells as well as in immune cells recruited to the inflamed intestinal mucosa determines the overall effect, ranging from a protective, anti-inflammatory modulation to a strong pro-inflammatory induction. Here we present the current advances in agonists and antagonists development and their potential therapeutic application studied in animal models of intestinal inflammation. In addition, alternative complementary approaches to manipulate such a complex signaling system are discussed, for example, the use of AR allosteric modulators or interference with Ado metabolism. Special features of the gut environment are taken into account: the contribution of diet components; the involvement of Ado in intestinal infections; the interactions with the gut microbiome, particularly, the recent exciting finding that an intestinal bacterium can directly produce extracellular Ado in response to host defense mechanisms in an inflammation scenario. Understanding each component of this dynamic system will broaden the possibilities for applying Ado signaling as a therapeutic target in gut inflammation.
嘌呤核苷腺苷(Ado)已被认识到在细胞应激情况下具有调节功能,如缺血、缺氧和炎症。细胞外腺苷作为免疫系统调节剂的重要性是一个备受关注的主题,也是胃肠道炎症领域最近日益关注的焦点。在本文中,讨论了腺苷信号在肠道炎症反应中的不同方面,考虑了四种已知的腺苷受体(AR;A(1)、A(2A)、A(2B)和 A(3))的贡献、它们的机制和表达模式。这些受体在上皮细胞和募集到炎症肠道黏膜的免疫细胞中的激活决定了整体效应,范围从保护性、抗炎调节到强烈的促炎诱导。在这里,我们介绍了在肠道炎症动物模型中研究的激动剂和拮抗剂的开发及其潜在的治疗应用的最新进展。此外,还讨论了操纵这种复杂信号系统的替代互补方法,例如使用 AR 变构调节剂或干扰腺苷代谢。还考虑了肠道环境的特殊特征:饮食成分的贡献;腺苷在肠道感染中的参与;与肠道微生物组的相互作用,特别是最近令人兴奋的发现,一种肠道细菌可以直接在炎症情况下产生细胞外腺苷,以响应宿主防御机制。理解这个动态系统的每个组成部分将扩大将腺苷信号作为肠道炎症治疗靶点的应用可能性。